Adamis Pharmaceuticals Units Drop 66% After $8M Offering Prices

Like
Comment
Favorite

Adamis Pharmaceuticals Units Drop 66% After $8M Offering Prices

Dow Jones2023-08-02

By Chris Wack

Adamis Pharmaceuticals units were down 66% at $1.37 after the company priced its public offering of 5.9 million units at $1.35 a unit.

The stock closed Tuesday's session up 179% on no news, and is down 95% in the past 12 months.

Each unit consists of one share of common stock and one warrant to buy one share of stock.

The warrants will be immediately exercisable at an exercise price of $1.35 a share and will expire five years from the date of issuance. The shares of stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.

Proceeds are expected to be $8 million. The offering is expected to close on Friday.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

August 02, 2023 11:09 ET (15:09 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

yong168
·2023-08-02
opioid and cannabis producers should invest in Adamis Pharmaceuticals: 1. Market Potential: Highlight the growing market demand for solutions to reduce opioid overdose deaths. With Adamis Pharmaceuticals' focus on R&D in this area, investing in the company could present a valuable opportunity to tap into a potentially lucrative market. 2. Positive Social Impact: Emphasize the positive social impact that reducing opioid overdose deaths can have on communities and families affected by addiction. By supporting Adamis Pharmaceuticals, these producers can contribute to saving lives and making a difference in the opioid crisis. 3. Diversification of Portfolio: Investing in a pharmaceutical company like Adamis can diversify their product portfolio and reduce dependency on a single industry
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2356376971?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-08-02 23:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2356376971","market":"us","top_or_hot":-1,"title":"Adamis Pharmaceuticals Units Drop 66% After $8M Offering Prices","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Adamis Pharmaceuticals units were down 66% at $1.37 after the company priced its public offering of 5.9 million units at $1.35 a unit. \n</p>\n<p>\n  The stock closed Tuesday's session up 179% on no news, and is down 95% in the past 12 months. \n</p>\n<p>\n  Each unit consists of one share of common stock and one warrant to buy one share of stock. \n</p>\n<p>\n  The warrants will be immediately exercisable at an exercise price of $1.35 a share and will expire five years from the date of issuance. The shares of stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. \n</p>\n<p>\n  Proceeds are expected to be $8 million. The offering is expected to close on Friday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 02, 2023 11:09 ET (15:09 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adamis Pharmaceuticals Units Drop 66% After $8M Offering Prices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdamis Pharmaceuticals Units Drop 66% After $8M Offering Prices\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-02 23:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Chris Wack \n\n\n \n\n\n  Adamis Pharmaceuticals units were down 66% at $1.37 after the company priced its public offering of 5.9 million units at $1.35 a unit. \n\n\n  The stock closed Tuesday's session up...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2356376971","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2356376971","pubTimestamp":1690988940,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Adamis Pharmaceuticals units were down 66% at $1.37 after the company priced its public offering of 5.9 million units at $1.35 a unit.The stock closed Tuesday's session up 179% on no news, and is down 95% in the past 12 months.Each unit consists of one share of common stock and one warrant to buy one share of stock.The warrants will be immediately exercisable at an exercise price of $1.35 a share and will expire five years from the date of issuance. The shares of stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.Proceeds are expected to be $8 million. The offering is expected to close on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4568":"美国抗疫概念"},"translate_title":"Adamis Pharmaceuticals股价下跌66%，发行价为800万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMP":1},"content_text":"By Chris Wack \n\n\n \n\n\n  Adamis Pharmaceuticals units were down 66% at $1.37 after the company priced its public offering of 5.9 million units at $1.35 a unit. \n\n\n  The stock closed Tuesday's session up 179% on no news, and is down 95% in the past 12 months. \n\n\n  Each unit consists of one share of common stock and one warrant to buy one share of stock. \n\n\n  The warrants will be immediately exercisable at an exercise price of $1.35 a share and will expire five years from the date of issuance. The shares of stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. \n\n\n  Proceeds are expected to be $8 million. The offering is expected to close on Friday. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 02, 2023 11:09 ET (15:09 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":204631111872536,"gmtCreate":1690991987208,"gmtModify":1690992962174,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"opioid and cannabis producers should invest in Adamis Pharmaceuticals: 1. Market Potential: Highlight the growing market demand for solutions to reduce opioid overdose deaths. With Adamis Pharmaceuticals' focus on R&amp;D in this area, investing in the company could present a valuable opportunity to tap into a potentially lucrative market. 2. Positive Social Impact: Emphasize the positive social impact that reducing opioid overdose deaths can have on communities and families affected by addiction. By supporting Adamis Pharmaceuticals, these producers can contribute to saving lives and making a difference in the opioid crisis. 3. Diversification of Portfolio: Investing in a pharmaceutical company like Adamis can diversify their product portfolio and reduce dependency on a single industry","listText":"opioid and cannabis producers should invest in Adamis Pharmaceuticals: 1. Market Potential: Highlight the growing market demand for solutions to reduce opioid overdose deaths. With Adamis Pharmaceuticals' focus on R&amp;D in this area, investing in the company could present a valuable opportunity to tap into a potentially lucrative market. 2. Positive Social Impact: Emphasize the positive social impact that reducing opioid overdose deaths can have on communities and families affected by addiction. By supporting Adamis Pharmaceuticals, these producers can contribute to saving lives and making a difference in the opioid crisis. 3. Diversification of Portfolio: Investing in a pharmaceutical company like Adamis can diversify their product portfolio and reduce dependency on a single industry","text":"opioid and cannabis producers should invest in Adamis Pharmaceuticals: 1. Market Potential: Highlight the growing market demand for solutions to reduce opioid overdose deaths. With Adamis Pharmaceuticals' focus on R&D in this area, investing in the company could present a valuable opportunity to tap into a potentially lucrative market. 2. Positive Social Impact: Emphasize the positive social impact that reducing opioid overdose deaths can have on communities and families affected by addiction. By supporting Adamis Pharmaceuticals, these producers can contribute to saving lives and making a difference in the opioid crisis. 3. Diversification of Portfolio: Investing in a pharmaceutical company like Adamis can diversify their product portfolio and reduce dependency on a single industry","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/204631111872536","repostId":2356376971,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}